Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

DSpace Repository

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

Author: Grob, Jean Jacques; Jouary, Thomas; Dreno, Brigitte; Asselineau, Julien; Gutzmer, Ralf; Hauschild, Axel; Leccia, Marie Therese; Landthaler, Michael; Garbe, Claus; Sassolas, Bruno; Herbst, Rudolf A.; Guillot, Bernard; Chene, Genevieve; Pehamberger, Hubert
Tübinger Autor(en):
Garbe, Claus
Published in: European Journal of Cancer (2013), Bd. 49, H. 1, S. 166-174
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: http://dx.doi.org/10.1016/j.ejca.2012.07.018
ISSN: 0959-8049
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)